The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Rapid Response Innovation Awards, 2008Identification of binding proteins for alpha-synuclein oligomers in brain and cells
Mutations in the PARK-1 and PARK-4 genes leads to alpha-synuclein aggregation with pathology eventually resembling that of sporadic PD. One question is whether the insoluble form of alpha-synuclein is...
-
Rapid Response Innovation Awards, 2008The Glucosylceramide Pathway in Parkinson's Disease and other Synucleinopathies: Genetic defects, Neuropathological characterization and cell culture models
Objective/Rationale:
Mutations in the beta glucocerebrosidase (GBA) gene are associated with Parkinson’s disease. Only a small number of neuropathologically confirmed PD, multiple system atrophy (MSA)... -
Community Fast Track, 2007Gene Therapy for Parkinson's Disease: Does Re-expression of HCN2 in GPe Improve Motor Deficits in Rodent PD Model?
Promising Outcomes of Original Grant:
We hypothesized that dopamine depletion in Parkinson’s disease results in downregulation of a specific ion channel, termed HCN2, in neurons of the external... -
Community Fast Track, 2007Elucidating the Role of Nurr1 in Protection of Adult Dopamine Neurons of the Substantia Nigra
Promising Outcomes of Original Grant:
Nurr1 is a transcription factor that is known to be important for the development of dopamine neurons. However, it continues to be expressed also in the adult... -
Community Fast Track, 2007The Protein Engrailed as a Potential Therapeutic Target in Parkinson's Disease
Promising Outcomes of Original Grant:
In our original grant, we have confirmed that a protein called Engrailed (which plays an important role both in the developping and in the adult dopaminergic... -
Community Fast Track, 2007CDNF - A Novel Conserved Neurotrophic Factor that Protects Midbrain Dopaminergic Neurons in vivo
Promising Outcomes of Original Grant:
Future treatment of Parkinson’s disease aim at therapies which would stop the progress of the disease and restore the function of injured dopamine nerves in the...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.